Immune Checkpoint Inhibitors in the Treatment of Renal Cell Carcinoma.

Abstract

Immune checkpoint inhibitors have quickly become a critical component to the management of advanced renal cell carcinoma. These therapies have been approved for patients who are treatment-naive and who have progressed on antiangiogenesis agents. Combinations of immune checkpoint inhibitors with antiangiogenesis agents show significant response rates and prolong survival. Adverse events associated with the use of checkpoint inhibition present unique challenges in the management of patients, and careful considerations are needed when checkpoint inhibitors are combined with antiangiogenesis agents. Nevertheless, the improvement in overall survival associated with these agents indicates that they will remain a vital component of kidney cancer treatment.

• Authors: Mamta Parikh, Poornima Bajwa
• Journal: Seminars in nephrology (Semin Nephrol) Vol. 40 Issue 1 Pg. 76-85 (01 2020) ISSN: 1558-4488 [Electronic] United States
• PMID: 32130969 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2019 Elsevier Inc. All rights reserved.

Chemical References

• Angiogenesis Inhibitors
• Antibodies, Monoclonal, Humanized
• Immune Checkpoint Inhibitors
• Ipilimumab
• Bevacizumab
• Nivolumab
• atezolizumab
• Axitinib
• pembrolizumab
• avelumab

Topics

• Adrenal Insufficiency (chemically induced)
• Angiogenesis Inhibitors (therapeutic use)
• Antibodies, Monoclonal, Humanized (therapeutic use)
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Axitinib (administration & dosage)
• Bevacizumab (administration & dosage)
• Carcinoma, Renal Cell (drug therapy)
• Colitis (chemically induced)
• Diabetes Mellitus, Type 1 (chemically induced)
• Exanthema (chemically induced)
• Fatigue (chemically induced)
• Hepatitis, Autoimmune (etiology)
• Humans
• Hypophysitis (chemically induced)
• Immune Checkpoint Inhibitors (therapeutic use)
• Ipilimumab (therapeutic use)
• Kidney Neoplasms (drug therapy)
• Myasthenia Gravis (chemically induced)
• Myocarditis (chemically induced)
• Nephritis (chemically induced)
• Nivolumab (therapeutic use)
• Pneumonia (chemically induced)
• Pruritus (chemically induced)
• Treatment Outcome